A new LNP-mRNA vaccine significantly boosts immune response and enhances BCG protection against tuberculosis, offering a ...
Researchers have engineered two mycobacterial strains with built-in kill switches that trigger self-destruction after immune ...
A new mRNA vaccine against tuberculosis (TB) is showing favorable results in preclinical trials. With only one currently ...
Currently, the most widely used vaccine against TB is the Bacillus Calmette-Guérin (BCG). Developed in 1921, the vaccine ...
The platform can be harnessed for TB, potentially improving protection and durability of immunity in a way that traditional ...
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
Hosted on MSN6d
Leprosy outbreak in Negeri Sembilan: Here’s everything you need to know about the diseaseLeprosy has caused one death in Kuala Pilah, Negeri Sembilan as of February 2025. Leprosy is not highly contagious ...
GlobalData on MSN5d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
In an interview with THE WEEK Dr Swapnil M. Khadake, HOD & Consultant Critical Care, Fortis Hiranandani Hospital talks about ...
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback